{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:44:51Z","timestamp":1792111491482,"version":"4.4.0"},"reference-count":62,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess plasma metabolome and lipidome changes associated with retatrutide treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Metabolomics and lipidomics were performed in fasting samples from 2 randomized, placebo-controlled phase 2 trials as a post hoc exploratory analysis. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. There were 282 and 213 participants in the obesity and T2D trials, respectively and the intervention(s) received were: Obesity trial: retatrutide (1, 4, 8, and 12 mg) or placebo; T2D trial: retatrutide (0.5, 4, 8, and 12 mg) or placebo or dulaglutide (1.5 mg). The main outcome measure(s) were changes in metabolite and lipid levels with retatrutide treatment against baseline levels and placebo using multiplicity correction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At both primary and study endpoints for both populations, higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid\u2013derived long-chain acylcarnitines. Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D. Retatrutide treatment was also associated with changes in metabolites associated with insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These changes were found in both study populations and sustained across study endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Retatrutide was associated with changes in 2 metabolic clusters related to fatty acid oxidation and insulin resistance in a direction associated with improved metabolic health and reduced cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag201","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:51:56Z","timestamp":1778673116000},"page":"3217-3228","source":"Crossref","is-referenced-by-count":1,"title":["Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes"],"prefix":"10.1210","volume":"111","author":[{"given":"Mackenzie J","family":"Pearson","sequence":"first","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A","family":"Willency","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhu","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkan","family":"Abadi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L","family":"Hartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Coskun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Duffin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B","family":"Newgard","sequence":"additional","affiliation":[{"name":"Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine , Durham, NC 27705 ,","place":["USA"]},{"name":"Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine , Durham, NC 27705 ,","place":["USA"]},{"name":"Department of Pharmacology and Cancer Biology, Duke University Medical Center , Durham, NC 27705 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-6943","authenticated-orcid":false,"given":"Valentina","family":"Pirro","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Cardiometabolic Research, , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"9","key":"2026101519591837600_dgag201-B1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"issue":"10401","key":"2026101519591837600_dgag201-B2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(23)01182-0","article-title":"A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena","volume":"402","author":"Bain","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"2026101519591837600_dgag201-B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"2026101519591837600_dgag201-B4","doi-asserted-by":"crossref","first-page":"171380","DOI":"10.1016\/j.peptides.2025.171380","article-title":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","volume":"187","author":"Bailey","year":"2025","journal-title":"Peptides"},{"issue":"15","key":"2026101519591837600_dgag201-B5","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"1","key":"2026101519591837600_dgag201-B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"2026101519591837600_dgag201-B7","doi-asserted-by":"crossref","first-page":"155346","DOI":"10.1016\/j.metabol.2022.155346","article-title":"Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity","volume":"138","author":"Angelidi","year":"2023","journal-title":"Metabolism"},{"issue":"6","key":"2026101519591837600_dgag201-B8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2026101519591837600_dgag201-B9","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"10401","key":"2026101519591837600_dgag201-B10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"2026101519591837600_dgag201-B11","doi-asserted-by":"crossref","first-page":"102073","DOI":"10.1016\/j.molmet.2024.102073","article-title":"Characterization of LY3324954 a long-acting glucagon-receptor agonist","volume":"91","author":"Roell","year":"2025","journal-title":"Mol Metab"},{"key":"2026101519591837600_dgag201-B12","doi-asserted-by":"crossref","first-page":"868037","DOI":"10.3389\/fendo.2022.868037","article-title":"Is glucagon receptor activation the thermogenic solution for treating obesity?","volume":"13","author":"Concei\u00e7\u00e3o-Furber","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026101519591837600_dgag201-B13","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"8","key":"2026101519591837600_dgag201-B14","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026101519591837600_dgag201-B15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/oby.2006.129","article-title":"Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification","volume":"14","author":"Getty-Kaushik","year":"2006","journal-title":"Obesity"},{"issue":"7","key":"2026101519591837600_dgag201-B16","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"2026101519591837600_dgag201-B17","doi-asserted-by":"crossref","unstructured":"Pearson MJ, Willency JA, Lin Y, et al \u00a0Supplementary data for \u201cRetatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes\u201d. Zenodo. Deposited May 2026. 10.5281\/zenodo.20160801","DOI":"10.1210\/clinem\/dgag201"},{"issue":"1","key":"2026101519591837600_dgag201-B18","doi-asserted-by":"crossref","first-page":"102884","DOI":"10.1016\/j.xpro.2024.102884","article-title":"Targeted metabolomics in human and animal biofluids and tissues using liquid chromatography coupled with tandem mass spectrometry","volume":"5","author":"Willency","year":"2024","journal-title":"STAR Protoc"},{"issue":"3","key":"2026101519591837600_dgag201-B19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1194\/jlr.D090795","article-title":"Three-phase liquid extraction: a simple and fast method for lipidomic workflows","volume":"60","author":"Vale","year":"2019","journal-title":"J Lipid Res"},{"issue":"1","key":"2026101519591837600_dgag201-B20","doi-asserted-by":"crossref","first-page":"18050","DOI":"10.1038\/s41598-018-36679-4","article-title":"Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation","volume":"8","author":"Norris","year":"2018","journal-title":"Sci Rep"},{"key":"2026101519591837600_dgag201-B21","author":"MathWorks"},{"issue":"1","key":"2026101519591837600_dgag201-B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/jors.160","article-title":"Mma: an R package for mediation analysis with multiple mediators","volume":"5","author":"Yu","year":"2017","journal-title":"J Open Res Softw"},{"key":"2026101519591837600_dgag201-B23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.sste.2017.02.001","article-title":"Exploring racial disparity in obesity: a mediation analysis considering geo-coded environmental factors","volume":"21","author":"Yu","year":"2017","journal-title":"Spat Spatiotemporal Epidemiol"},{"issue":"3","key":"2026101519591837600_dgag201-B24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nm995","article-title":"Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance","volume":"10","author":"An","year":"2004","journal-title":"Nat Med"},{"issue":"10","key":"2026101519591837600_dgag201-B25","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","article-title":"Carnitine transport and fatty acid oxidation","volume":"1863","author":"Longo","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2026101519591837600_dgag201-B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/metabo11010051","article-title":"L-Carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine","volume":"11","author":"McCann","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"2026101519591837600_dgag201-B27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1152\/physrev.00028.2023","article-title":"Hepatic glucagon action: beyond glucose mobilization","volume":"104","author":"Kajani","year":"2024","journal-title":"Physiol Rev"},{"issue":"1","key":"2026101519591837600_dgag201-B28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.011008.145616","article-title":"Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation","volume":"49","author":"Shimizu","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2026101519591837600_dgag201-B29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12967-025-06341-5","article-title":"Comprehensive review of the expanding roles of the carnitine pool in metabolic physiology: beyond fatty acid oxidation","volume":"23","author":"Xiang","year":"2025","journal-title":"J Transl Med"},{"issue":"4","key":"2026101519591837600_dgag201-B30","doi-asserted-by":"crossref","first-page":"e146000","DOI":"10.1172\/jci.insight.146000","article-title":"Metabolic flexibility across the spectrum of glycemic regulation in youth","volume":"6","author":"Bacha","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"2026101519591837600_dgag201-B31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"issue":"4","key":"2026101519591837600_dgag201-B32","doi-asserted-by":"crossref","first-page":"e124079","DOI":"10.1172\/jci.insight.124079","article-title":"The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI Insight"},{"issue":"6514","key":"2026101519591837600_dgag201-B33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"issue":"8","key":"2026101519591837600_dgag201-B34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"2026101519591837600_dgag201-B35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cvr\/cvaf004","article-title":"Therapeutic potential of ketone bodies on exercise intolerance in heart failure: looking beyond the heart","volume":"121","author":"Soni","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026101519591837600_dgag201-B36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fneur.2019.00585","article-title":"Ketone bodies in neurological diseases: focus on neuroprotection and underlying mechanisms","volume":"10","author":"Yang","year":"2019","journal-title":"Front Neurol"},{"key":"2026101519591837600_dgag201-B37","doi-asserted-by":"crossref","first-page":"782657","DOI":"10.3389\/fnut.2021.782657","article-title":"Neuroprotection by the ketogenic diet: evidence and controversies","volume":"8","author":"Gough","year":"2021","journal-title":"Front Nutr"},{"issue":"1","key":"2026101519591837600_dgag201-B38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ijms25010124","article-title":"Molecular mechanisms of neuroprotection by ketone bodies and ketogenic diet in cerebral ischemia and neurodegenerative diseases","volume":"25","author":"Jang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2026101519591837600_dgag201-B39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/nu17071268","article-title":"Investigating the therapeutic potential of the ketogenic diet in modulating neurodegenerative pathophysiology: an interdisciplinary approach","volume":"17","author":"Shabbir","year":"2025","journal-title":"Nutrients"},{"issue":"20","key":"2026101519591837600_dgag201-B40","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1113\/jphysiol.2009.175489","article-title":"Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity","volume":"587","author":"Schenk","year":"2009","journal-title":"J Physiol"},{"issue":"1","key":"2026101519591837600_dgag201-B41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ijo.2014.70","article-title":"Relatively low endogenous fatty acid mobilization and uptake helps preserve insulin sensitivity in obese women","volume":"39","author":"Van Pelt","year":"2015","journal-title":"Int J Obes"},{"issue":"4","key":"2026101519591837600_dgag201-B42","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"2026101519591837600_dgag201-B43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101519591837600_dgag201-B44","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1152\/ajpendo.00334.2019","article-title":"Dietary branched-chain amino acid restriction alters fuel selection and reduces triglyceride stores in hearts of Zucker fatty rats","volume":"318","author":"McGarrah","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"2026101519591837600_dgag201-B45","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.molmet.2016.04.006","article-title":"Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export","volume":"5","author":"White","year":"2016","journal-title":"Mol Metab"},{"issue":"6427","key":"2026101519591837600_dgag201-B46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aav0558","article-title":"Branched-chain amino acids in disease","volume":"363","author":"White","year":"2019","journal-title":"Science"},{"issue":"1","key":"2026101519591837600_dgag201-B47","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41467-021-21962-2","article-title":"Branched-chain \u03b1-ketoacids are preferentially reaminated and activate protein synthesis in the heart","volume":"12","author":"Walejko","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"2026101519591837600_dgag201-B48","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2026101519591837600_dgag201-B49","doi-asserted-by":"crossref","first-page":"e10883","DOI":"10.1371\/journal.pone.0010883","article-title":"alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population","volume":"5","author":"Gall","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"2026101519591837600_dgag201-B50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2337\/dc15-2752","article-title":"\u03b1-Hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance","volume":"39","author":"Cobb","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"2026101519591837600_dgag201-B51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/metabo11120835","article-title":"Which role plays 2-hydroxybutyric acid on insulin resistance?","volume":"11","author":"Sousa","year":"2021","journal-title":"Metabolites"},{"issue":"10","key":"2026101519591837600_dgag201-B52","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1172\/JCI64801","article-title":"2-Aminoadipic acid is a biomarker for diabetes risk","volume":"123","author":"Wang","year":"2013","journal-title":"J Clin Invest"},{"key":"2026101519591837600_dgag201-B53","doi-asserted-by":"crossref","first-page":"1569020","DOI":"10.3389\/fphar.2025.1569020","article-title":"Metabolite 2-aminoadipic acid: implications for metabolic disorders and therapeutic opportunities","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"2026101519591837600_dgag201-B54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"issue":"24","key":"2026101519591837600_dgag201-B55","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.3390\/jcm13247616","article-title":"Gout and hyperuricemia: a narrative review of their comorbidities and clinical implications","volume":"13","author":"Timsans","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"2026101519591837600_dgag201-B56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4314\/ahs.v21i1.13","article-title":"Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials","volume":"21","author":"Zong","year":"2021","journal-title":"Afr Health Sci"},{"issue":"4","key":"2026101519591837600_dgag201-B57","first-page":"708","article-title":"Effect of glucagon on renal excretion of oxypurinol and purine bases","volume":"24","author":"Yamamoto","year":"1997","journal-title":"J Rheumatol"},{"key":"2026101519591837600_dgag201-B58","doi-asserted-by":"crossref","first-page":"155955","DOI":"10.1016\/j.metabol.2024.155955","article-title":"Characterization of the plasma metabolome and lipidome in response to sleeve gastrectomy and gastric bypass surgeries reveals molecular patterns of surgical weight loss","volume":"158","author":"Bagheri","year":"2024","journal-title":"Metabolism"},{"issue":"5","key":"2026101519591837600_dgag201-B59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/metabo12050458","article-title":"Metabolomics in bariatric and metabolic surgery research and the potential of deep learning in bridging the gap","volume":"12","author":"Pantelis","year":"2022","journal-title":"Metabolites"},{"issue":"4","key":"2026101519591837600_dgag201-B60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diaspect.25.4.200","article-title":"Comparison of bariatric surgical procedures for diabetes remission: efficacy and mechanisms","volume":"25","author":"Vetter","year":"2012","journal-title":"Diabetes Spectr"},{"issue":"8","key":"2026101519591837600_dgag201-B61","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.2337\/db13-0185","article-title":"Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism","volume":"62","author":"Magkos","year":"2013","journal-title":"Diabetes"},{"issue":"8","key":"2026101519591837600_dgag201-B62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag201\/68289072\/dgag201.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3217\/68289072\/dgag201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3217\/68289072\/dgag201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:59:31Z","timestamp":1792108771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/11\/3217\/8678492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag201","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,5,14]]}}}